Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Inovio Pharmaceuticals (INO) PT Raised to $14 at RBC Capital
March 15, 2018 8:25 AM EDTRBC Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining an Outperform rating.
Analyst Gregory Renza notes the pipeline continues to progress as VGX-3100 continues to ramp up with broad CIN site expansion.
... More